Large study finds women taking GLP-1 medications developed breast cancer at significantly lower rates than non-users.
Women taking GLP-1 drugs like Ozempic and Wegovy were 30% less likely to develop breast cancer in a study of over 100,000 women. Among the 15,264 women using these medications, only 1.62% were diagnosed with breast cancer compared to 2.47% of non-users. The protective effect held across age groups, races, and body weights, suggesting something beyond just the weight loss these drugs cause.
This isn't about the drugs directly fighting cancer cells in some dramatic way. GLP-1 medications appear to improve several metabolic factors that influence breast cancer risk: they reduce chronic inflammation, improve insulin sensitivity, and alter hormone levels in addition to promoting weight loss. Think of it as fixing the underlying conditions that make cancer more likely to develop, rather than targeting cancer itself.
The findings matter because current breast cancer prevention drugs have serious side effects that limit their use. If GLP-1s prove protective in clinical trials, they could offer a more tolerable prevention option for higher-risk women who are already candidates for these medications due to diabetes or obesity. However, this was an observational study, not a clinical trial designed to test cancer prevention.
What You Can Actually Do Today
- Ask your doctor about breast cancer risk assessment if you're over 25, especially if you have family history or other risk factors
- Schedule annual mammograms starting at 40 (or 35 if you live in a high-risk area like Connecticut)
- Focus on the proven prevention basics: maintain a BMI under 25, exercise 30 minutes daily, limit alcohol to special occasions
This research doesn't prove GLP-1 drugs prevent cancer. These medications aren't FDA-approved for cancer prevention.
